Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Cliff Rims und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, HLA-DRB1 Chains, Epitopes, T-Lymphocyte, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Peer Reviewed Medical Research Program, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is associated with high-risk HLA class II alleles known as the “RA shared epitope.” Among prevalent shared epitope alleles, study of DRB1*04:04 has been limited. To define relevant epitopes, we identified citrullinated peptide sequences from synovial antigens that were predicted to bind to HLA-DRB1*04:04 and utilized a systematic approach to confirm their binding and assess their recognition by CD4 T cells. After confirming the immunogenicity of 13 peptides derived from aggrecan, cartilage intermediate layer protein (CILP), α-enolase, vimentin, and fibrinogen, we assessed their recognition by T cells from a synovial tissue sample, observing measurable responses to 8 of the 13 peptides. We then implemented a multicolor tetramer panel to evaluate the frequency and phenotype of antigen-specific CD4 T cells in individuals with anti-citrullinated protein antibody-positive RA and controls. In subjects with RA, CILP-specific T-cell frequencies were significantly higher than those of other antigens. The surface phenotypes exhibited by antigen-specific T cells were heterogeneous, but Th1-like and Th2-like cells predominated. Stratifying based on disease status and activity, antigen-specific T cells were more frequent and most strongly polarized in RA subjects with high disease activity. In total, these findings identify novel citrullinated epitopes that can be used to interrogate antigen-specific CD4 T cells and show that antigen-specific T-cell frequency is elevated in subjects with high disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
- VA National Rheumatology Program, Specialty Care Program Office, Washington DC, USA.
- Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, USA.
- Department of Rheumatology, Virginia Mason Medical Center, Seattle, WA, USA.
ORCID-Profile: Cliff Rims, Sylvia E Posso, Jeffrey Carlin, William W Kwok, Jane H Buckner, Eddie A James
Förderung
- NIAID NIH HHS
- Peer Reviewed Medical Research Program
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Rims, C., Uchtenhagen, H., Brooks, K., Ng, B., Posso, S. E., Carlin, J., Kwok, W. W., Buckner, J. H., & James, E. A. (2025). Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae102
Vancouver
Rims C, Uchtenhagen H, Brooks K, Ng B, Posso SE, Carlin J, et al. Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae102
BibTeX
@article{Rims2025,
author = {Rims, Cliff and Uchtenhagen, Hannes and Brooks, Kadin and Ng, Bernard and Posso, Sylvia E and Carlin, Jeffrey and Kwok, William W and Buckner, Jane H and James, Eddie A},
title = {Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae102}
}
EUVIMED